Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation [2]

Annals of Pharmacotherapy

Volumn 36, Issue 12, 2002, Pages 1971-1972

  Ibrahim, Rami B ^a   Abella, Esteban M ^b   Chandrasekar, Pranathathi H ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZITHROMYCIN; CEFTRIAXONE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; FLUDARABINE; METHYLPREDNISOLONE; PENICILLIN V; RANITIDINE; SUMATRIPTAN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BONE MARROW TRANSPLANTATION; BREATHING; CANCER GRADING; CASE REPORT; CREATININE BLOOD LEVEL; DONOR; FEVER; HEALTH STATUS; HUMAN; INTERSTITIAL PNEUMONIA; INTESTINE; LABORATORY TEST; LETTER; LYMPHOCYTOPENIA; MALE; MIGRAINE; OPEN LUNG BIOPSY; OUTPATIENT; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINUSITIS; SKIN; THORAX RADIOGRAPHY; TREATMENT WITHDRAWAL; UREA NITROGEN BLOOD LEVEL; WESTERN HEMISPHERE; WHOLE BODY RADIATION; BLOOD; DRUG INTERACTION;

ADULT; BONE MARROW TRANSPLANTATION; CLARITHROMYCIN; DRUG INTERACTIONS; HUMANS; MALE; TACROLIMUS;

EID: 0036897034     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C117     Document Type: Letter

References (9)

1. Lee TJ, Kennedy LA. Tacrolimus: An alternative for graft-versus-host disease prevention. Ann Pharmacother 2000;34:377-81.
2. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997;16:267-78.
3. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a livingdonor small bowel recipient. Clin Pharmacol Ther 2000;68:98-103.
4. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant 2001;28:753-8.
5. Przepiorka D, Nash RA, Wingard JR, Zhu J, Maher RM, Fitzsimmons WE, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Bone Marrow Transplant 1999:5:94-7.
6. Wolter K, Wagner K, Philipp T, Fritschka E. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994;47:207-8.
7. Gomez G, Alvarez ML, Errasti P, Lavilla FJ, Garcia N, Ballester B, et al. Acute tacrolimus nephrotoxicity in renal transplant patients treatment with clarithromycin. Transplant Proc 1999;31:2250-1.
8. Katari SR, Magnone M, Shapiro R, Jordan M, Scantlebury V. Vivas C, et al. Clinical features of acute reversible tacrolimus nephrotoxicity in kidney transplantation recipients. Clin Transplant 1997;11:237-42.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981:30:239-45.